Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use KOMZIFTI safely and effectively. See full prescribing information for KOMZIFTI. KOMZIFTITM (ziftomenib) capsules, for oral useInitial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options [see Dosage and Administration (2.1), Clinical Pharmacology (12.1), and Clinical Studies (14)].
- generic_name
- ziftomenib
- product_names
- ziftomenib
- ndc
- 84696-200, 84696-200-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en